Profile data is unavailable for this security.
About the company
Hubei Jumpcan Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of drugs. The Company focuses on the research and development, production and sales of drugs in the fields of pediatrics, respiratory system, digestive system and gynecology. The Company's main products include Xiao’er Chiqiao Qingre Keli, Pudilan Anti-inflammatory Oral Liquid, Huanglong Anti-cough Keli, Iron Proteinsuccinylate Oral Solution, Fuyanshu Capsules and others. The Company's products are mainly used in children's wind-heat cold with stagnation, clearing heat and detoxification, upper respiratory tract infectious diseases, acute and chronic bronchitis, gastrointestinal diseases, gynecology and other fields. The Company mainly operates its businesses in the domestic market.
- Revenue in CNY (TTM)6.14bn
- Net income in CNY1.65bn
- Incorporated1997
- Employees5.03k
- LocationHubei Jumpcan Pharmaceutical Co LtdBaotawan, Daqing West Road, Taixing CityTAIZHOU 225441ChinaCHN
- Phone+86 52 389719161
- Fax+86 52 389719009
- Websitehttps://www.jumpcan.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Joincare Pharmaceutical Group Ind. Co. | 15.20bn | 1.37bn | 20.87bn | 14.35k | 15.39 | 1.40 | -- | 1.37 | 0.7413 | 0.7413 | 8.24 | 8.13 | 0.4211 | 2.40 | 5.51 | 1,059,126.00 | 8.29 | 8.60 | 17.45 | 18.66 | 61.28 | 62.42 | 19.70 | 17.66 | 2.38 | -- | 0.1776 | 27.59 | -6.17 | 5.45 | -3.90 | 9.17 | 6.84 | 4.56 |
| Tasly Pharmaceutical Group Co Ltd | 8.35bn | 1.10bn | 21.92bn | 10.96k | 19.96 | 1.78 | -- | 2.63 | 0.7348 | 0.7348 | 5.59 | 8.24 | 0.525 | 1.83 | 7.50 | 761,658.60 | 6.44 | 5.86 | 7.91 | 7.26 | 65.70 | 58.62 | 12.26 | 10.61 | 3.12 | -- | 0.0642 | 56.80 | -2.03 | -14.86 | -10.78 | -0.9327 | -5.02 | 9.94 |
| Bloomage Biotechnology Corp Ltd | 4.66bn | 64.62m | 22.76bn | 4.44k | 338.86 | 3.20 | -- | 4.88 | 0.1394 | 0.1394 | 9.59 | 14.76 | 0.5431 | 1.12 | 8.61 | 1,048,475.00 | 0.719 | 8.43 | 0.827 | 9.97 | 70.71 | 75.45 | 1.32 | 12.34 | 1.42 | 40.02 | 0.0317 | 30.32 | -11.61 | 23.29 | -70.59 | -21.53 | 9.89 | -21.54 |
| Zhejiang Huahai Pharmaceutical Co., Ltd. | 8.71bn | 468.07m | 23.52bn | 9.07k | 48.25 | 2.47 | -- | 2.70 | 0.3256 | 0.3256 | 6.00 | 6.35 | 0.4279 | 0.9611 | 3.17 | 960,689.80 | 2.18 | 5.67 | 3.15 | 7.93 | 59.76 | 60.79 | 5.10 | 11.66 | 0.7399 | 8.95 | 0.4519 | 31.74 | 14.91 | 12.12 | 34.74 | 14.46 | 18.47 | 6.58 |
| Suzhou Zelgen Biopharmaceuticals Co Ltd | 742.28m | -133.34m | 24.99bn | 910.00 | -- | 21.75 | -- | 33.67 | -0.5038 | -0.5038 | 2.80 | 4.34 | 0.2482 | 0.446 | 4.77 | 815,689.40 | -4.56 | -17.15 | -8.23 | -25.89 | 89.95 | 93.14 | -18.36 | -118.33 | 1.72 | -- | 0.4949 | -- | 37.91 | -- | 50.52 | -- | 44.66 | -- |
| Hubei Jumpcan Pharmaceutical Co Ltd | 6.14bn | 1.65bn | 25.04bn | 5.03k | 15.11 | 1.81 | -- | 4.08 | 1.80 | 1.80 | 6.69 | 15.02 | 0.3543 | 2.99 | 3.59 | 1,222,407.00 | 9.53 | 15.19 | 11.67 | 19.57 | 75.44 | 81.73 | 26.91 | 26.02 | 5.18 | -- | 0.0437 | 46.90 | -16.96 | 2.93 | -10.32 | 9.30 | -20.43 | 11.19 |
| Kangmei Pharmaceutical Co Ltd | 5.28bn | 16.64m | 26.14bn | 4.23k | 1,643.48 | 3.64 | -- | 4.95 | 0.0012 | 0.0012 | 0.3973 | 0.5197 | 0.3785 | 1.64 | 2.23 | 1,246,204.00 | 0.1368 | -21.82 | 0.2232 | -42.17 | 17.12 | -92.73 | 0.3614 | -108.18 | 0.7875 | -- | 0.0162 | -- | 6.47 | -14.63 | -91.64 | -- | -33.46 | -- |
Data as of Feb 13 2026. Currency figures normalised to Hubei Jumpcan Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
2.97%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 9.84m | 1.08% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2025 | 3.58m | 0.39% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 3.44m | 0.38% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 2.44m | 0.27% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 2.17m | 0.24% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 1.65m | 0.18% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 1.45m | 0.16% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 967.23k | 0.11% |
| Broad Fund Management Co. Ltd.as of 30 Jun 2025 | 837.40k | 0.09% |
| Rongtong Fund Management Co., Ltd.as of 30 Jun 2025 | 799.50k | 0.09% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
